AzacitidineMethylationAntimetabolites, AntineoplasticMyelodysplastic SyndromesDNA MethylationLeukemia, Myelomonocytic, ChronicCpG IslandsDNA Modification MethylasesChromatography, Supercritical FluidEpigenesis, GeneticEpigenomicsCompassionate Use TrialsLeukemia, Myeloid, AcuteDNA (Cytosine-5-)-MethyltransferasePromoter Regions, GeneticInjections, SubcutaneousAnemia, RefractoryConsolidation ChemotherapySulfitesAnemia, Refractory, with Excess of BlastsInduction ChemotherapyCytosineGene SilencingDrug ApprovalMethyltransferasesHistonesTreatment Outcome5-MethylcytosineGenomic ImprintingSurvivalHistone-Lysine N-MethyltransferaseDNA-Cytosine MethylasesLong Interspersed Nucleotide ElementsInternational AgenciesProtein MethyltransferasesUnited States Food and Drug AdministrationThalidomideDrug Administration ScheduleS-AdenosylmethionineCell Line, TumorBase SequenceLysineDinucleoside PhosphatesProtein-Arginine N-MethyltransferasesAntimetabolitesRemission InductionLeukemia, MyeloidBiological AvailabilityMolecular Sequence DataDNA, NeoplasmBlood TransfusionCytarabineDNATetrazolium SaltsAntineoplastic Combined Chemotherapy ProtocolsPolymerase Chain ReactionGene Expression Regulation, NeoplasticGenes, p16RNA, Long NoncodingDeoxyribonuclease HpaIIS-AdenosylhomocysteineSequence Analysis, DNAChromatinMaximum Tolerated DoseEnzyme InhibitorsDeath-Associated Protein KinasesTranscription, GeneticPrognosisTumor Suppressor ProteinsSite-Specific DNA-Methyltransferase (Adenine-Specific)Genes, Tumor SuppressorFatigueAcute DiseaseRetrospective StudiesDisease ProgressionSurvival AnalysisGenome, HumanCyclin-Dependent Kinase Inhibitor p16RecurrenceGene Expression RegulationAcetylationMutationRNA, UntranslatedHematopoietic Stem Cell Transplantation